US92532F1003 - Common Stock - After market: 323.1 0 (0%)
NASDAQ:VRTX (1/31/2023, 7:07:35 PM)+3.12 (+0.98%)
|GICS Sector||Health Care|
|Earnings (Last)||01-24 2023-01-24/amc||Earnings (Next)||05-03 2023-05-03/amc|
|Ins Owners||0.18%||Inst Owners||92.98%|
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 3,900 full-time employees. The firm is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF) and it has several ongoing clinical and research programs to advance and extend treatment of CF. The firm's marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Its four medicines are being used to treat the people with CF in North America, Europe and Australia. The firm has a pipeline of investigational therapies in other serious diseases where it is leveraging insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. The Company’s other pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS 02210
CEO: Reshma Kewalramani
The gene-therapy specialist's near-term outlook is quite bullish.
These healthcare giants have plenty of room left to run.
These companies have the therapies to boost revenue for a decade.
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time.
Fast-growing, underappreciated stocks to buy are trading at a steep discount and will reward investors as they rise in value.
Here you can normally see the latest stock twits on VRTX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.